HC Wainwright Issues Positive Forecast for Innoviva Earnings

Key Points

• HC Wainwright raised Innoviva’s FY2026 earnings forecast to $2.30 per share from $2.20 and maintained a “Buy” rating with a $46 price target. The firm also estimates $0.62 EPS for Q2 2027 and $2.37 EPS for FY2027.
• Analyst sentiment is mixed: four firms rate Innoviva a Buy and two rate it a Sell, resulting in an overall “Hold” consensus and an average price target of $34.75.
• Innoviva shares opened at $20.75, with a market capitalization of about $1.53 billion and a 12-month trading range of $16.52 to $25.15. Institutional investors own approximately 99.12% of the stock.

Innoviva, Inc. (NASDAQ:INVA - Free Report) - Research analysts at HC Wainwright boosted their FY2026 earnings estimates for shares of Innoviva in a note issued to investors on Monday, August 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of $2.30 per share for the year, up from their previous estimate of $2.20. HC Wainwright currently has a "Buy" rating and a $46.00 target price on the stock. The consensus estimate for Innoviva's current full-year earnings is $2.20 per share. HC Wainwright also issued estimates for Innoviva's Q2 2027 earnings at $0.62 EPS and FY2027 earnings at $2.37 EPS.

INVA has been the subject of a number of other reports. BTIG Research reaffirmed a "buy" rating and set a $42.00 price target on shares of Innoviva in a report on Monday, June 22nd. Zacks Research downgraded Innoviva from a "hold" rating to a "strong sell" rating in a report on Friday, July 31st. Cantor Fitzgerald cut their target price on Innoviva from $36.00 to $34.00 and set an "overweight" rating on the stock in a research report on Friday, August 7th. Wall Street Zen cut Innoviva from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, Weiss Ratings reaffirmed a "buy (b)" rating on shares of Innoviva in a report on Wednesday, June 24th. Four investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $34.75.

Innoviva Stock Performance

NASDAQ:INVA opened at $20.75 on Wednesday. The firm has a market capitalization of $1.53 billion, a PE ratio of 5.06 and a beta of 0.35. The business's fifty day moving average price is $22.02 and its 200 day moving average price is $22.32. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.01 and a quick ratio of 15.18. Innoviva has a 12 month low of $16.52 and a 12 month high of $25.15.

Hedge Funds Weigh In On Innoviva

Several large investors have recently bought and sold shares of INVA. Vanguard Group Inc. increased its position in shares of Innoviva by 11.6% during the fourth quarter. Vanguard Group Inc. now owns 7,917,103 shares of the biotechnology company's stock worth $158,263,000 after purchasing an additional 819,757 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Innoviva in the 2nd quarter valued at about $77,562,000. Dimensional Fund Advisors LP boosted its position in shares of Innoviva by 1.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company's stock valued at $103,366,000 after purchasing an additional 76,026 shares during the period. State Street Corp grew its stake in Innoviva by 9.4% during the 4th quarter. State Street Corp now owns 2,796,820 shares of the biotechnology company's stock worth $55,908,000 after buying an additional 239,848 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in Innoviva by 38.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,358,633 shares of the biotechnology company's stock worth $43,045,000 after buying an additional 650,151 shares during the last quarter. Institutional investors and hedge funds own 99.12% of the company's stock.

About Innoviva

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva's portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source